MedPath

Early Health Warning Intervention in Tobacco Control

Not Applicable
Conditions
Smoking Cessation
Interventions
Other: early health warning intervention
Registration Number
NCT04996329
Lead Sponsor
Peking University First Hospital
Brief Summary

This is a multi-center, randomized, controlled intervention clinical trial. A total of 1000 current smokers with rapid decline in lung function will be recruited and equally divided into two groups, comprehensive smoking cessation intervention group (early health warning intervention combined with brief smoking cessation intervention) and brief smoking cessation intervention group. It is aimed to evaluate whether early health warning intervention will increase the rate of smoking cessation.

Detailed Description

This is a multi-center, randomized, controlled intervention clinical trial. A total of 1,000 current smokers ( ≥ 10 pack-years) with rapid decline in lung function will be recruited from Predictive Value of Inflammatory Biomarkers and FEV1 for COPD (PIFCOPD) study (clinical trails. gov ID NCT03532893) after 1 year of follow-up. Subjects will be qually divided into two groups, comprehensive smoking cessation intervention group (early health warning intervention combined with brief smoking cessation intervention) and brief smoking cessation intervention group. Health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD. The Department of Respiratory and Critical Care of Peking University First Hospital is responsible for this research. Other 9 units participating in the study, include the The Second Hospital of Hebei Medical University, Henan Provincial People's Hospital, The Second Hospital of Jilin University, The First Affiliated Hospital of Xi'an Jiaotong University, Shandong Provincial Hospital Affiliated to Shandong University, Shan xi Dayi Hospital(Shanxi Academy of Medical Sciences), Tianjin Medical University General Hospital, The Affiliated Hospital of Inner Mongolia University. Some questionnaire about tobacco dependence, depression, anxiety, the willingness to quit smoking and withdrawal symptoms will be collected. Exhaled CO will be measured. Subjects will recived 6 times of smoking cessation intervention in 6 month and followed in another 6 month. The primary outcome is the rate of quitting smoking. The study protocol has been approved by the Peking University First Hospital Institutional Review Board (IRB) (2019-255). Any protocol modifications will be submitted for the IRB review and approval.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
1000
Inclusion Criteria
  1. aged at 40-75 years old;
  2. FEV1/FVC>70% after inhaled bronchodilator
  3. current smoker (≥ 10 pack-years)
  4. rate of FEV1 decline >30ml/y
  5. lived in a community for more than 1 years and has no plans to move out in the next 4 years
Exclusion Criteria
  1. history of asthma, COPD, lung cancer, active pulmonary tuberculosis, bronchiectasis, diffuse lung disease (interstitial pneumonia, pulmonary sarcoidosis, occupational lung disease, sarcoidosis et al) and pleural disease;
  2. history of lobectomy and / or lung transplantation;
  3. predicted life expectancy less than 3 years;
  4. history of severe psychiatric illnesses, mental disorders, neurological disorders, malignant tumors, chronic liver disease, heart failure, autoimmune diseases, chronic kidney disease;
  5. Alcoholism, drug abuse or abuse of toxic solvents;
  6. Cannot finish long term follow-up or poor compliance;
  7. Do not provide consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
brief smoking cessation intervention groupearly health warning interventionbrief smoking cessation intervention only
comprehensive smoking cessation intervention groupearly health warning interventionEarly health warning intervention combined with brief smoking cessation intervention Early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD
Primary Outcome Measures
NameTimeMethod
rate of quitting smoking1 year

keep smoking cessation for more than 6 months

Secondary Outcome Measures
NameTimeMethod
relapse rate1 year

relapse rate of smoking

one month smoking cessation rate6 months

stop smoking for more than one month, but less than six months

smoking reduction rate1 year

less than the number of cigarettes before the first intervention

smoking cessation rate at each follow-up6 months

stop smoking for 24 hours or more

Trial Locations

Locations (10)

The Second Hospital of Jilin University

🇨🇳

Ch'ang-ch'un, China

Shanxi Bethune Hospital

🇨🇳

Taiyuan, China

The Affiliated Hospital of Inner Mongolia Medical University

🇨🇳

Hohhot, China

Shandong Provincial Hospital Affiliated to Shandong University

🇨🇳

Jing'an, China

The Second Hospital of Hebei Medical University

🇨🇳

Shijia Zhuang, China

Henan Provincial People's Hospita

🇨🇳

Zhenzhou, China

The First Hospital of Qinhuangdao

🇨🇳

Qinhuangdao, China

Tianjin Medical University General Hospital

🇨🇳

Tianjin, China

The First Affiliated Hospital of Xi'an Jiaotong University

🇨🇳

Xi'an, China

Peking University First Hospital

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath